Published in final edited form as:

Org Biomol Chem. 2017 April 05; 15(14): 2979–2992. doi:10.1039/c7ob00448f.

The design and synthesis of an α -Gal trisaccharide epitope that provides a highly specific anti-Gal immune response

Kensaku Anraku^{+,a,b}, Shun Sato^{+,a,c}, Nicholas T. Jacob^{+,a}, Lisa M. Eubanks^a, Beverly A. Ellis^a, and Kim D. Janda^{*,a}

^aDepartments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, The Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute 10550 N Torrey Pines Rd BCC-582, La Jolla, CA 92037 USA

^bDepartment of Medical Technology, Kumamoto Health Science University, 325 Izumi-machi, Kita-ku, Kumamoto 861-5598, Japan

^cResearch Institute for Sustainable Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba Central 5-2, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan

Abstract

Carbohydrate antigens displaying Gal α (1,3)Gal epitopes are recognized by naturally occurring antibodies in humans. These anti-Gal antibodies comprise up to 1% of serum IgG and has been viewed as detrimental as they are responsible for hyperacute organ rejections. In order to model this condition, α (1,3)galactosyltransferase-knockout mice are inoculated against the Gal α (1,3)Gal epitope. In our study, two α -Gal trisaccharide epitopes composed of either Gal α (1,3)Gal β (1,4)GlcNAc or Gal α (1,3)Gal β (1,4)Glc linked to a squaric acid ester moiety were examined for their ability to elicit immune response in KO mice. Both target epitopes were synthesized using a two-component enzymatic system using modified disaccharide substrates containing a linker moiety for coupling. While both glycoconjugate vaccines induced the required high anti-Gal IgG antibody titers, it was found that this response had exquisite specificity for the Gal α (1,3)Gal β (1,4)GlcNAc hapten used, with little cross reactivity with the Gal α (1,3)Gal β (1,4)Glc hapten. Our findings indicate that while homogenous glycoconjugate vaccines provide high IgG titers, the carrier and adjuvanting factors can deviate the specificity to an antigenic determinant outside the purview of interest.

Introduction

The α -Gal epitope (Gal α 1-3Gal) is a common type-2 terminus abundantly synthesized on lipids and proteins of non-primate mammals and New World monkeys through glycosylation via α 1,3galactosyltransferase (α 1,3GalT).^{1,2} Interestingly, this epitope is absent in humans and Old World monkeys because the α 1,3GalT gene was inactivated in ancestral Old World

kdjanda@scripps.edu; Tel: +1-858-784-2516; Fax: +1-858-784-2595.

⁺These authors contributed equally to this work

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here].
See DOI: 10.1039/x0xx00000x

primates millions of years ago.^{2,3,4} The lack of this epitope results in high levels of naturally-occurring anti-Gal antibodies (Abs), which constitute ~1% of circulating immunoglobulins.⁵ The presence of large amounts of anti-Gal Abs is a key primary factor in the acute and hyperacute rejection of xenotransplants.^{6,7,8,9}

Typically, in order to recapitulate the physiologic condition of α -Gal Abs in an animal model, α 1,3GalT knockout (KO) mice¹⁰ are inoculated with the α -Gal epitope via vaccination with rabbit red blood cells (RRBCs) or pig kidney membranes (PKM) homogenates having a high concentration of α -Gal epitopes. However, this method often results in a high production of anti-Gal IgM, with IgG production lower than in humans.^{11,12} Our initial attempts to utilize RRBC ghosts to immunize KO mice also resulted in a primarily IgM response that failed to produce memory (Supp. Fig 1).

It has been established that the α -Gal disaccharide exhibits a high degree of conformational flexibility,¹³ but the addition of even a single sugar unit severely impacts this flexibility.¹⁴ Inhibition studies indicate that the preferred target antigen in the anti-Gal response is Gal α (1,3)Gal β (1,4)GlcNAc.^{15,16} However, structural insights suggest that there is no conformational difference between Gal α (1-3)Gal β (1-4)Glc and Gal α (1-3)Gal β (1-4)GlcNAc (Fig. 1),¹⁴ and as a result are often used interchangeably when designing a hapten for a glycoconjugate vaccine.^{13,14,17,18,19}

During the course of our investigations using haptens based on both the Gal α (1-3)Gal β (1-4)GlcNAc and Gal α (1-3)Gal β (1-4)Glc epitopes, we discovered exquisite discrimination of the immune response between these two. Our findings demonstrated that while cross-reactivity is dominant with xenoreactive materials (RRBCs, PKM homogenate), the immune response can be tailored to a singular carbohydrate epitope if glycoside-pure materials are evaluated in the vaccination process, and that care must be taken in achieving a relevant approximation of the human condition of the anti-Gal response.

Results

Design of α -Gal epitopes

We designed α -Gal trisaccharide epitopes composed of either Gal α (1,3)Gal β (1,4)Glc or Gal α (1,3)Gal β (1,4)GlcNAc linked to a squaric acid ester moiety via 2-aminoethyl, 2-(2-aminoethoxy)ethyl, and 2-[2-(2-aminoethoxy)ethoxy]ethyl spacers (compounds **1–6**, Fig. 2). We varied the lengths of the spacer in an effort to determine its influence in inducing anti-Gal Abs. The squaric acid ester functionality serves as a handle that can be easily conjugated to carrier proteins via condensation with lysine residues of the protein.^{20,21} We note that synthetic methods for the preparation of α -Gal trisaccharides have been reported, however, these involved a need to control selectivity during the glycosylation step.^{22,23} We devised a strategy utilizing a chemoenzymatic reaction mediated by α (1,3)galactosyltransferase (α 1,3GalT) for incorporating the terminal galactose to disaccharides, which resulted in the facile preparation of our targeted α -Gal epitopes.²⁴

Syntheses of the Gal α (1,3)Gal β (1,4)Glc epitopes

The syntheses of the Gal α (1,3)Gal β (1,4)Glc epitopes were performed as shown in Scheme 1. Coupling of lactose peracetate **7** with 2-chloroethanol in the presence of BF₃·Et₂O to give **8** proceeded in 52% yield.²⁵ The reaction of peracetate **7** and 2-(2-chloroethoxy)ethanol was, however, inefficient (< 10% yield). Therefore, we utilized the chloroacetimidate strategy to append the 2-(2-chloroethoxy)ethyl and 2-[2-(2-chloroethoxy)ethoxy]ethyl linker moieties.²⁶ This was accomplished by treatment of **7** with hydrazine acetate to selectively remove the anomeric acetyl group, followed by nucleophilic addition of trichloroacetonitrile using DBU to give the α -isomer of compound **9**. The activated chloroacetimidate **9** readily reacted with 2-(2-chloroethoxy)ethanol or 2-[2-(2-chloroethoxy)ethoxy]ethanol in the presence of BF₃·Et₂O to give β -isomer of compounds **10** and **11** in 58% and 44% yield, respectively. Subsequent azidation and global deacetylation of compounds **8**, **10**, and **11** gave the azido-disaccharide intermediates, which were then used as substrates for the α 1,3GalT-mediated incorporation of the terminal galactose. Enzymatic reactions were carried out in 50 mM Tris buffer (pH 7.0) containing 10 mM MnCl₂ at 37 °C (see Experimental Procedure) to give the α (1,3)-linked trisaccharides **15**–**17** in 34–54% yield. A unique ¹H-NMR peak was observed as a doublet at δ 5.15–5.18 ppm (in D₂O solvent), which corresponds to the proton at the 1-position of an α (1,3)-linked galactose.²⁷ Reduction of azido compounds **15**–**17** to their corresponding primary amines followed by squarate coupling gave the target epitopes **1**–**3** in 39–66% yield.

Syntheses of the Gal α (1,3)Gal β (1,4)GlcNAc epitopes

The starting material *N*-acetylglucosamine **18** was prepared using the method of Wrodnigg et al.^{28,29} Peracetylation of **18** followed by reaction with TMSOTf gave the oxazoline intermediate **20**, which was then coupled to azido-ethanol, 2-(2-azidoethoxy)ethanol or 2-[2-(2-azidoethoxy)ethoxy]ethanol under acidic conditions to yield compounds **21**–**23** (Scheme 2).³⁰ Subsequent deacetylation followed by α 1,3GalT-mediated appendage of galactose gave the α (1,3)-linked trisaccharides **24** and **25**. An alternative strategy to access α (1,3)-linked trisaccharides is by exploiting two enzymatic systems [galactose 4-epimerase (GalE) and α 1,3GalT] using the inexpensive UDP-glucose as the substrate. In this case, UDP-glucose is first catalytically converted *in situ* by GalE to UDP-galactose, which is then utilized as the substrate of α 1,3GalT (Fig. 3). Such two-component enzyme system worked to afford compounds **25** and **26** in 52 and 57% yield, respectively. Hydrogenation of **24**–**26** to their corresponding primary amines followed by condensation with squaric acid ethyl ester furnished the target epitopes **4**–**6**.

Hapten conjugation, vaccination and α -Gal titer determination—Targeted α -Gal epitopes **1**–**6** were conjugated to either immunogenic carrier protein keyhole limpet hemocyanin (KLH) or tetanus toxoid (TT) via amidation of the squaric acid moieties under basic borate buffer conditions.²¹ In addition to alum,³¹ preliminary results utilizing a Gal α (1-3)Gal β (1-4)GlcNAc glycoconjugate as well as RRBC ghosts indicated that the formulation benefited from the use of the glycolipid adjuvant C34 (Supp. Fig 1). C34 has been shown to generally induce a class switch from IgM to IgG in mice.³² The efficacies of the synthetic α -Gal conjugate vaccines were determined by vaccination of α 1,3GalT-

knockout mice (50 μ g α -Gal conjugate/mouse).^{10,33} The vaccine schedule of **1**-, **2**-, and **3**-conjugated KLH were 2-week interval injections for a total of 3 administrations (see experimental procedure). Anti-Gal antibody titers of mouse serum samples were determined by ELISA using compound **3**-BSA as the coating antigen (Fig. 4). Titers at 42 days were similar over the course of vaccination schedule in IgG (Midpoint IC₅₀; **1**:30,866, **2**:30,556, **3**:28,753) but different for IgM (Midpoint IC₅₀; **1**:7,000, **2**:2,386, **3**:6,169). KLH, while an efficient T-cell epitope, presents difficulty in quantifying the conjugation efficiency. Thus, we changed to tetanus toxoid (TT) conjugated to a Gal α (1,3)Gal β (1,4)GlcNAc type trisaccharide. In this series, **4**-, **5**-, and **6**-TT glycoconjugates were administered at 0, 4, and 8 weeks in an effort to increase the class-switching to IgG and stimulate a memory response (see experimental procedure). Antibody titers of mouse serum samples were determined by ELISA using compound **6**-BSA as the coating antigen (Fig. 4). Titers at 51 days were different over the course of vaccination schedule in IgG (Midpoint IC₅₀; **4**:31,203, **5**:60,748, **6**:43,568) and in IgM (Midpoint IC₅₀; **4**:193, **5**:2,084, **6**:2,000). The low IgM titers for these mice was preferable as it indicated an efficient memory IgG response was engendered. Furthermore, compound **5** having the 2-(2-aminoethoxy)ethyl linker trisaccharide results in the highest titer values of all six haptens, indicating this linker length is preferable to maximize the IgG titres than that of other linker lengths (compounds **4** and **6**). Sham-vaccinated mice showed no appreciable titer.

α -Gal antibody specificity—Among the three TT-conjugates, **5**-TT which contains the 2-(2-aminoethoxy)ethyl linker, elicited Abs with the highest titers as determined by ELISA. In order to assess the specificity of the α -Gal antibodies induced by **5**-TT vaccination, we performed competitive ELISA in the presence of varying concentrations (0, 0.6, 6.0, and 60 μ M) of either the Gal α (1,3)Gal β (1,4)Glu **2** or Gal α (1,3)Gal β (1,4)GlcNAc **5** epitope. As depicted in Fig. 5, Gal α (1,3)Gal β (1,4)Glc **2** showed no inhibitory effect up to 60 μ M (Fig. 5a) whereas the Gal α (1,3)Gal β (1,4)GlcNAc **5** epitope displayed a concentration-dependent inhibition (with approximate IC₅₀ of ~6.0 μ M; Fig. 5b) of the Ab-antigen binding. Moreover, the squaric acid ethylester attached to the 2-(2-aminoethoxy)ethyl spacer (but devoid of the trisaccharide unit) also showed no inhibition of antigen binding, indicating that the Abs specifically recognize the α -Gal epitope but not the linker moiety (data not shown). Our results exemplify the exquisite specificity of **5**-TT-elicited Abs for the Gal α (1,3)Gal β (1,4)GlcNAc-type epitope over Gal α (1,3)Gal β (1,4)Glc.

Discussion

The role of carbohydrates as key biological ligands is well established. Yet, in stark comparison to peptides and proteins, carbohydrates have been notoriously difficult structures to develop effective vaccines against. This low immunogenicity has been attributed to the flexibility and high solvation of glycans.³⁴ In order to improve the response, it is often necessary to engender greater T-cell help via conjugation of the desired carbohydrate epitope to a T-cell epitope carrier.³⁴ We employed this strategy in order to achieve high levels of IgG titers in mice. Studies often use the Gal α (1–3)Gal β (1–4)GlcNAc and Gal α (1–3)Gal β (1–4)Glc epitopes interchangeably, as the natural antibody response is primarily directed against the α -Gal terminus.^{13,14} However, evidence suggests that part of the natural Ab

response to α Gal is directed against the Gal β (1–4)GlcNAc portion of the trisaccharide.¹⁴ This has been attributed to the relative inflexibility of the Gal β (1–4)GlcNAc glycosidic linkage.

We prepared two highly homologous α -Gal epitopes, Gal α (1,3)Gal β (1,4)GlcNAc and Gal α (1,3)Gal β (1,4)Glc, both predicated upon a chemoenzymatic reaction with α 1,3GalT. Using disaccharide substrates functionalized with an ethylene glycol linker, a two-component enzymatic synthesis provided rapid access to these two haptens. In addition, this synthetic scheme was greatly enhanced by utilizing GalE.²² This allowed the preparation of the very expensive but essential intermediate, UDP-galactose substrate, which was obtained from the inexpensive UDP-glucose.

With facile routes to Gal α (1,3)Gal β (1,4)GlcNAc and Gal α (1,3)Gal β (1,4)Glc epitopes, antibody selectivity could be evaluated and thus vaccination of these carbohydrate epitopes was initiated. To enhance the vaccination process, a glycosphingolipid bearing an α -galactosyl headgroup and acyl chain terminated with a phenyl moiety, termed C34, was also added to the vaccine cocktail.³² C34 has been shown to induce a class switch from IgM to IgG in mice. Utilizing this vaccine, high levels of anti-Gal IgG were achieved (Fig. 4), but it is clear that this response has a specificity for the reducing end of the glycone.

α -Gal antibodies in humans readily cross-react with a variety of xenoantigens bearing the α -Gal terminus, the lack of antibody cross-reactivity pattern seen between the Gal α (1,3)Gal β (1,4)GlcNAc and Gal α (1,3)Gal β (1,4)Glc epitope-vaccines we have prepared (See Fig. 5) demonstrates an exquisite discrimination between these two epitopes. This result clearly indicates that the *N*-acetyl moiety is the key element in antigen recognition by these antibodies generated by both vaccines. We hypothesize this is due to the conformational stability imparted by the additional residue at the reducing end of the oligosaccharide. This stability may provide a higher stochastic exposure of this antigenic determinant during synapse formation, thus driving specificity to this end and outcompeting the response to the terminus. While this subtle change in a single functional group drastically alters antibody recognition, cases of antibody discrimination between these two functional groups has been documented and thus highlight the subtle importance of steric and electronic effects in determining antibody-carbohydrate epitope recognition. Similar discrimination has been reported in the isolation of anti-Gal monoclonal Abs,³⁵ but not in a polyclonal response. Our results demonstrate the ability of this glycoconjugate formulation to discriminate these epitopes almost entirely in the polyclonal response.

Conclusion

In summary a highly efficient, cost-effective chemoenzymatic route has been developed to achieve glycoconjugate vaccines for two common α -Gal haptens. Anti-Gal Abs represent a significant portion of the natural antibody repertoire in humans, and are contentious agents in xenotransplantation. The naturally occurring α -Gal antibody repertoire binds with several modes to α -Gal termini. However, utilizing two chemically pure Gal α (1,3)Gal epitopes, we were able to generate a highly honed immune response able to discriminate the Gal α (1,3)Gal β (1,4)GlcNAc and Gal α (1,3)Gal β (1,4)Glc epitopes. The importance of an *N*-

acetyl for a hydroxyl group substitution between these two epitopes was critical in polyclonal selectivity seen. The information and materials garnered from this campaign are expected to facilitate future vaccine and monoclonal antibody development for both cancer-related as well as drugs of abuse treatments.

Materials and methods

General Methods

^1H and ^{13}C NMR spectra were obtained using a Bruker 500 or 600 MHz instrument unless otherwise noted. Chemical shifts were reported in parts per million (ppm, δ) referenced to the residual ^1H resonance of the solvent (CDCl_3 , 7.26 ppm) or (CD_3OD , 3.31 ppm). ^{13}C spectra were referenced to the residual ^{13}C resonance of the solvent (CDCl_3 , 77.0 ppm) or (CD_3OD , 49.0 ppm). Splitting patterns were designated as follows: s, singlet; br, broad; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet). Electrospray Ionization (ESI) mass were obtained on a ThermoFinnigan LTQ Ion Trap. Analytical thin layer chromatography (TLC) was performed on Merck precoated analytical plates, 0.25 mm thick, silica gel 60 F254. Preparative TLC (PTLC) separations were performed on Merck analytical plates (0.50 mm thick) precoated with silica gel 60 F254. Flash chromatography separations were performed on Aldrich silica gel (60 Å pore size, 40–63 μm particle size, 230–400 mesh). The LC/MS analysis was performed using an Agilent G-1956D single quadrupole mass spectrometer equipped with an 1100 series LC system from Agilent Technologies. HPLC separations were performed on a Vydac 218TP C_{18} reversed phase preparative (10–15 μm) HPLC column using a gradient of acetonitrile and water. High resolution mass spectra were obtained in the Scripps Center for Mass Spectrometry. Protein concentration was determined by BCA assay (Pierce BCA Protein Assay Kit) with analysis on a plate reader (Molecular Devices SpectraMax 250) at 562 nm³⁶, and determination of copy number of protein conjugates was carried out using comparative MALDI-MS, using sinapinic acid as the matrix on an Applied Biosystems VoyagerDE STR MS³⁷.

Enzyme Expression

The vectors pET15b-GalE and pET15b- α 1,3galT encoding the enzymes Galactose-4-epimerase (GalE), and α 1,3-Galactosyltransferase (α 1,3GalT), respectively, were a generous gift from Prof. Peng George Wang. Proteins were overexpressed in the *E. coli* expression strain BL21(DE3) (Invitrogen) and purified using TALON® metal affinity resin (Clontech). For GalE expression, 50 mL LB/Ampicillin (100 $\mu\text{g}/\text{mL}$) culture was inoculated with an overnight culture and grown at 37°C with shaking (250 rpm) to an $\text{OD}_{600} \sim 0.6$ followed by the addition of isopropyl-1-thio- β -D-galactoside at a final concentration of 0.5 mM. Cells were grown for an additional 3 h at 37°C with shaking and subsequently, harvested by centrifugation at 5837 rpm (~ 4000 rcf) and 4°. The cell pellet yield was $\sim 0.22\text{g}$ per 50 mL culture. For α 1,3GalT expression, cell growth was conducted at 20°C and continued for an additional 18 h after IPTG induction. Approximately 0.30 g of cell paste was obtained for α 1,3GalT. Cell pellets were stored at -80°C until further processing.

Purification of Enzymes

Cell pellets were thawed on ice and then lysed with 5 mL of 0.2 g/L lysozyme (Sigma) in 20 mM Sodium phosphate buffer (pH 7.0) containing 1% Triton X-100. Cells were disrupted by gentle pipetting followed by incubation at 37°C on rotator for 20 min. Subsequently, a 5 μ L aliquot of a 2,000 unit/mL DNase I stock (New England Biolab) was added to the solution, followed by further incubation for 20 min at 37°C on rotator. The soluble fraction of the cell lysate was obtained by centrifugation at 13,200 rpm (~16,000 rcf) and 4°C for 20 min and was added to 2 mL of TALON resin (Clontech) pre-equilibrated with 20 mM Sodium phosphate buffer (pH 7.0) containing 0.3 M NaCl. The column was washed with 10 mL of 20 mM Sodium phosphate buffer (pH 7.0) containing 0.3 M NaCl and the protein was eluted using a step gradient with increasing concentrations of imidazole (20, 50, 100, and 200 mM) in 20 mM Sodium phosphate buffer (pH 7.0) containing 0.3 M NaCl. Protein purity in each 5 mL fraction was visualized by SDS-PAGE (supplementary information 2). Fractions containing pure enzyme were pooled and concentrated to ~0.3–0.5 mL using an Amicon 4 centrifugal filter (MWCO 10-kDa) followed by dialysis against PBS. The final enzyme solution was added to equal volume of glycerol to make a 50% glycerol solution for storage at –20°C. Protein concentration was determined by BCA method. Overall protein yield from a 50 mL culture was ~1.5 mg for GalE and ~1.4 mg for α 1,3GalT.

Synthesis of 1-position modified β -D-galactopyranosyl-(1,3)- β -D-galactopyranosyl-(1,4)- β -D-glucopyranoside)-2-ethoxycyclobutene-3,4-dione derivatives

2-Chloroethyl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1,4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (8)—To a mixture of Lactose peracetate **7** (5.0 g, 7.36 mmol) and 2-chloroethanol (0.494 mL, 7.36 mmol) in CH_2Cl_2 (50 mL) was added by dropwise addition of $\text{BF}_3\cdot\text{Et}_2\text{O}$ (1.20 mL, 9.58 mmol) at 0 °C over a time course of 20 min. The mixture was diluted with CH_2Cl_2 and washed with ice H_2O and saturated aqueous NaHCO_3 (two times), dried over Na_2SO_4 , and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (Pentane:AcOEt=1:1) to afford **8** (2.69 g, 52%) as a yellow oil.

^1H NMR (500 MHz, Chloroform-*d*) δ 5.33 (dd, J = 3.5, 1.2 Hz, 1H, H-4'), 5.19 (t, J = 9.3 Hz, 1H, H-3), 5.09 (dd, J = 10.4, 7.9 Hz, 1H, H-2'), 4.94 (dd, J = 10.4, 3.4 Hz, 1H, H-3'), 4.90 (dd, J = 9.5, 7.9 Hz, 1H, H-2), 4.53 (d, J = 7.9 Hz, 1H, H-1'), 4.51 – 4.45 (m, 2H, H-1, H-6a), 4.21 – 3.97 (m, 4H, H-6b, H-6a', H-6b', OCH₂H), 3.88 – 3.83 (m, 1H, H-5'), 3.82 – 3.68 (m, 2H, H-4, OCH₂H), 3.67 – 3.52 (m, 3H, H-5, CH₂Cl), 2.14, 2.11, 2.05, 2.04, 2.03, 2.03, 1.95 (7 x s, 21H, 7 x COCH₃). ^{13}C NMR (500 MHz, Chloroform-*d*) δ 170.70, 170.49, 170.41, 170.08, 170.07, 169.42, 101.44, 101.24, 76.54, 73.14, 72.97, 71.82, 71.35, 71.09, 70.31, 69.50, 66.99, 62.24, 61.19, 42.79, 21.22, 21.17, 21.08, 21.01, 20.88. MS (ESI), m/z 699.1900 ($\text{M} + \text{H}$)⁺ ($\text{C}_{28}\text{H}_{39}\text{ClO}_{18}$ requires 699.1898). TLC; R_f 0.29 (Pentane:AcOEt=1:1).

2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1,4)-2,3,6-tri-O-acetyl- α -D-glucopyranose trichloracetimidate (9)—To a mixture of Lactose peracetate **7** (0.5 g, 0.74 mmol) in DMF (5 mL) was added hydrazine acetate (0.73 g, 0.81 mmol). Upon completion of anomeric deacetylation by TLC, 1 mL of water was added to the mixture and concentrated in vacuo. The residue was diluted with AcOEt (20 mL) and washed with 1%

HCl (20 ml), saturated NaHCO₃ (20 ml), and Brine (20 ml), and the organic phase was dried over Na₂SO₄. The organic phase was filtered and concentrated in vacuo to give the crude glycosyl hemiacetal. The dried crude glycosyl hemiacetal compound in CH₂Cl₂ (10 ml) was treated with DBU (0.044 ml, 0.30 mmol) and to the solution was added trichloroacetonitrile (0.22 ml, 2.2 mmol) at 0°C and stirred at room temperature for 3 hrs. The mixture was concentrated and purified by silica gel column chromatography (Hexane:AcOEt=1:1) to give compound **9** as yellow oil (0.337 g, 58%).

The spectrum for compound **9** was the same as reported previously for the α isomer²⁴. ¹H NMR (500 MHz, Chloroform-*d*) δ 8.65 (s, 1H, NH), 6.47 (d, *J* = 3.8 Hz, 1H, H-1), 5.54 (t, *J* = 9.7 Hz, 1H, H-3), 5.34 (d, *J* = 3.4 Hz, 1H, H-4'), 5.19 – 4.99 (m, 2H, H-2, H-2'), 4.94 (dd, *J* = 10.4, 3.4 Hz, 2H, H-3'), 4.61 – 4.36 (m, 2H, H-6a, H-1'), 4.20 – 4.01 (m, 4H, H-5, H-6b, H-6a', H-6b'), 3.97 – 3.75 (m, 2H, H-4, H-5'), 2.14, 2.09, 2.08 – 2.01, 1.99, 1.95 (s, 21H, 7 x COCH₃). TLC; R_f 0.34 (Pentane:AcOEt=1:1).

2-(2-Chloroethoxy)ethyl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1,4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (10)—To a mixture of chloroimide **8** (0.244 g, 0.312 mmol) and 2-(2-chloroethoxy)ethanol (0.037 ml, 0.343 mmol) in CH₂Cl₂ (50 ml) was added by dropwise addition of BF₃·Et₂O (1.20 ml, 9.58 mmol) at –20 °C over a time course of 30 min and stirred at room temperature for 3 hrs. The mixture was neutralized with Et₃N (0.056 ml, 0.4 mmol) and concentrated in vacuo. The residue was purified by preparative Thin layer chromatography (CH₂Cl₂:AcOEt=1:1) to afford **10** (0.134 g, 58%) as a yellow oil.

¹H NMR (500 MHz, Chloroform-*d*) δ 5.34 (dd, *J* = 3.5, 1.2 Hz, 1H, H-4'), 5.19 (t, *J* = 9.3 Hz, 1H, H-3), 5.10 (dd, *J* = 10.4, 7.9 Hz, 1H, H-2'), 4.95 (dd, *J* = 10.4, 3.5 Hz, 1H, H-3'), 4.89 (dd, *J* = 9.5, 7.9 Hz, 1H, H-2), 4.56 (d, *J* = 7.8 Hz, 1H, H-1'), 4.52 – 4.46 (m, 2H, H-1, H-6a), 4.17 – 4.04 (m, 3H, H-6b, H-6a', H-6b'), 3.91 (ddd, *J* = 11.0, 4.8, 3.6 Hz, 1H, OCHH), 3.86 (ddd, *J* = 7.4, 6.3, 1.2 Hz, 1H, H-5'), 3.79–3.56 (m, 8H, OCHH, OCH₂, CH₂O, CH₂Cl, H-5), 2.14, 2.11, 2.07–2.00, 1.96 (7 x s, 21H, COCH₃). ¹³C NMR (126 MHz, CDCl₃) δ 170.49, 170.48, 170.27, 170.19, 169.89, 169.80, 169.20 (7 x COCH₃), 101.20, 100.71, 76.37, 72.94, 72.81, 71.80, 71.55, 71.13, 70.83, 70.46, 69.26, 69.19, 66.75, 62.10, 60.93, 42.9, 21.01, 20.95, 20.87, 20.77, 20.64. MS (ESI), *m/z* 765.1978 (M + Na)⁺ (C₃₀H₄₃ClO₁₉ requires 765.1979). TLC; R_f 0.71 (CH₂Cl₂:AcOEt=1:1).

2-[2-(2-Chloroethoxy)ethoxy]ethyl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1,4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (11)—Chloroimide **9** (0.276 g, 0.353 mmol) and 2-[2-(2-chloroethoxy)ethoxy]ethanol (0.041 ml, 0.282 mmol) were allowed to react under the same condition as described for the preparation of **10** to give **11** (0.096 g, 44%) as a colorless oil.

¹H NMR (400 MHz, Chloroform-*d*) δ 5.30 (dd, *J* = 3.4, 1.1 Hz, 1H, H-4'), 5.15 (t, *J* = 9.3 Hz, 1H, H-3), 5.06 (dd, *J* = 10.4, 7.9 Hz, 1H, H-2'), 4.91 (dd, *J* = 10.4, 3.4 Hz, 1H, H-3'), 4.85 (dd, *J* = 9.6, 7.9 Hz, 1H, H-2), 4.53 (d, *J* = 7.9 Hz, 1H, H-1'), 4.49 – 4.37 (m, 2H, H-1, H-6a), 4.13 – 4.00 (m, 3H, H-6b, H-6a', H-6b'), 3.92 – 3.52 (m, 15H, H-4, H-5', 3 x OCH₂, 2 x CH₂O, CH₂Cl, H-5), 2.11, 2.08, 2.02, 2.00, 1.92 (7 x s, 21H, COCH₃). ¹³C NMR (101

MHz, CDCl₃) δ 170.39, 170.37, 170.17, 170.08, 169.79, 169.68, 169.09, 101.11, 100.65, 76.31, 72.85, 72.68, 71.70, 71.41, 71.03, 70.71, 70.70, 70.42, 69.15, 69.10, 66.67, 62.06, 60.86, 42.84, 20.92, 20.86, 20.77, 20.69, 20.68, 20.67, 20.55. MS (ESI), m/z 787.2419 (M + H)⁺ (C₃₂H₄₇ClO₂₀ requires 787.2422). TLC; R_f 0.55 (CH₂Cl₂:AcOEt=1:1).

2-Azidoethyl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1,4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (12)—To a solution of **8** (0.0841 g, 0.12 mmol) in DMF (4 ml) was added sodium azide (78.2 mg, 1.20 mmol). The mixture was stirred at 60 °C for 48 h. The solvent was removed under reduced pressure, and the residue was diluted with AcOEt and washed with H₂O, dried over Na₂SO₄, and then concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography (Pentane:AcOEt=1:1) to afford **12** (0.0652 g, 77%) as a colorless oil.

¹H NMR (500 MHz, Chloroform-*d*) δ 5.34 (dd, J = 3.4, 1.2 Hz, 1H, H-4'), 5.19 (t, J = 9.2 Hz, 1H, H-3), 5.10 (dd, J = 10.4, 7.9 Hz, 1H, H-2'), 4.97 – 4.88 (m, 2H, H-3', H-2), 4.55 (d, J = 7.9 Hz, 1H, H-1'), 4.52 (dd, J = 12.0, 2.2 Hz, 1H, H-6a), 4.49 (d, J = 7.8 Hz, 1H, H-1), 4.17 – 4.03 (m, 3H, H-6b, H-6a', H-6b'), 3.98 (ddd, J = 10.6, 5.0, 3.4 Hz, 1H, OCHH), 3.86 (ddd, J = 7.5, 6.3, 1.3 Hz, 1H, H-5'), 3.84 – 3.77 (m, 1H, H-4), 3.67 (ddd, J = 10.6, 8.2, 3.3 Hz, 1H, OCHH), 3.61 (ddd, J = 9.9, 5.0, 2.2 Hz, 1H, H-5), 3.46 (ddd, J = 13.3, 8.2, 3.4 Hz, 1H, CHHN₃), 3.26 (ddd, J = 13.4, 5.0, 3.3 Hz, 1H, CHHN₃), 2.14, 2.11, 2.05, 2.04, 1.95 (s, 21H, 7 x COCH₃). ¹³C NMR (126 MHz, CDCl₃) δ 170.45, 170.25, 170.17, 169.86, 169.79, 169.18, 101.22, 100.58, 76.28, 72.95, 72.87, 71.63, 71.10, 70.83, 69.26, 68.77, 66.74, 61.92, 60.92, 50.65, 20.97, 20.92, 20.84, 20.76, 20.63. MS (ESI), m/z 728.2121 (M + H)⁺ (C₂₈H₃₉N₃O₁₈ requires 728.2102). TLC; R_f 0.34 (Pentane:AcOEt=1:1).

2-(2-Azidoethoxy)ethyl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1,4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (13)—Compound **10** (0.061 g, 0.0775 mmol) was allowed to react under the same condition as described for the preparation of **12** to give **13** (0.030 g, 52%) as a colorless oil.

¹H NMR (500 MHz, Chloroform-*d*) δ 5.33 (dd, J = 3.5, 1.2 Hz, 1H, H-4'), 5.19 (t, J = 9.3 Hz, 1H, H-3), 5.09 (dd, J = 10.4, 7.9 Hz, 1H, H-2'), 4.94 (dd, J = 10.4, 3.4 Hz, 1H, H-3'), 4.89 (dd, J = 9.5, 7.9 Hz, 1H, H-2), 4.56 (d, J = 7.9 Hz, 1H, H-1'), 4.52 – 4.45 (m, 2H, H-1, H-6a), 4.15 – 4.03 (m, 3H, H-6b, H-6a', H-6b'), 3.91 (dt, J = 11.1, 4.4 Hz, 1H, OCHH), 3.86 (ddd, J = 7.5, 6.3, 1.2 Hz, 1H, H-5'), 3.79 (t, J = 9.4 Hz, 1H, H-4), 3.72 (ddd, J = 10.9, 6.6, 4.1 Hz, 1H, OCHH), 3.66 – 3.56 (m, 5H, OCH₂, CH₂O, H-5), 3.38 – 3.32 (m, 2H, CH₂N₃), 2.14, 2.11, 2.05, 2.03, 1.95 (s, 21H, COCH₃). ¹³C NMR (101 MHz, CDCl₃) δ 170.49, 170.47, 170.27, 170.19, 169.88, 169.81, 169.19, 101.18, 100.74, 76.37, 72.91, 72.77, 71.81, 71.12, 70.80, 70.49, 70.31, 69.23, 69.20, 66.73, 62.09, 60.92, 50.88, 21.00, 20.95, 20.84, 20.78, 20.77, 20.76, 20.65. MS (ESI), m/z 750.2563 (M + H)⁺ (C₃₀H₄₃N₃O₁₉ requires 750.2562). TLC; R_f 0.19 (Pentane:AcOEt=1:1).

2-[2-(2-azidoethoxy)ethoxy]ethyl 2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1,4)-2,3,6-tri-O-acetyl- β -D-glucopyranoside (14)—Compound **11** (0.3 g, 0.381 mmol) was allowed to react under the same condition as described for the preparation of **13** to give **14** (0.241 g, 84%) as a colorless oil.

¹H NMR (400 MHz, Chloroform-*d*) δ 5.34 (dd, *J* = 3.5, 1.2 Hz, 1H, H-4'), 5.19 (t, *J* = 9.3 Hz, 1H, H-3), 5.10 (dd, *J* = 10.4, 7.9 Hz, 1H, H-2'), 4.94 (dd, *J* = 10.4, 3.4 Hz, 1H, H-3'), 4.89 (dd, *J* = 9.6, 7.9 Hz, 1H, H-2), 4.56 (d, *J* = 7.9 Hz, 1H, H-1'), 4.52 – 4.41 (m, 2H, H-1, H-6a), 4.18 – 4.02 (m, 3H, H-6b, H-6a', H-6b), 3.95 – 3.84 (m, 2H, OCH₂H, H-5'), 3.78 (t, *J* = 9.5 Hz, 1H, H-4), 3.75 – 3.54 (m, 10H, H-5, OCH₂H, 2 x OCH₂, 2 x CH₂O), 3.39 (t, *J* = 5.0 Hz, 2H, CH₂N₃), 2.14, 2.11, 2.05, 2.05 – 2.00, 1.96 (s, 21H, COCH₃). ¹³C NMR (126 MHz, CDCl₃) δ 170.72, 170.69, 170.49, 170.40, 170.12, 170.00, 169.42, 101.45, 100.99, 76.65, 73.19, 73.00, 72.04, 71.36, 71.08, 71.06, 70.76, 70.42, 69.49, 69.41, 66.98, 62.39, 61.17, 51.05, 21.23, 21.18, 21.07, 21.00, 20.87. MS (ESI), *m/z* 794.2828 (M + H)⁺ (C₃₂H₄₇N₃O₂₀ requires 794.2826). TLC; *R*_f 0.51 (CH₂Cl₂:AcOEt=1:1).

2-Azidoethyl α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-β-D-glucopyranoside (15)—To a solution of **12** (0.044 g, 0.0569 mmol) in dry MeOH (10 ml) was added 0.5 M NaOMe (0.224 ml, 0.112 mmol). The mixture was stirred at room temperature for 5 h, and then neutralized with CH₃COOH (0.0064 ml, 0.112 mmol). The mixture was concentrated in vacuo, and the residue was partially purified by silica gel column chromatography (CH₂Cl₂:MeOH=3:1 to 1:1) to afford deacetylate crude compound, and an aliquot of this compound was used for enzyme reaction without further purification. To a solution of 5 mM UDP-Galactose and 4 mM deacetylated compound (0.0123 g, 0.03 mmol) in 50 mM Tris-HCl (pH 7.0) supplemented with 10 mM MnCl₂ was added 1,3αGalT (20 μg/mL) to a final volume of 7.5 ml. The solution was incubated at 37°C with agitation and reaction progress was monitored by TLC. When the deacetylated compound was consumed, α1,3GalT was removed from reaction mixture using an Amicon 4 filter (MWCO 10-kDa) by centrifugation at 7,830 rpm and room temperature for 15 min. Filtrates were concentrated in vacuo, and the residue was dissolved in H₂O and then passed through a chloride anion-exchange column [Dowex 1 (Cl⁻)]. The eluate was concentrated and the residue was purified on a VYDAC C₁₈ reversed phase semipreparative (250 mm × 22 mm, 10–15 μm) HPLC column using H₂O and 0.1% TFA in CH₃CN mobile phases. A linear gradient was employed (95:5 H₂O/0.1% TFA in CH₃CN → 5:95 H₂O/0.1% TFA in CH₃CN) over a period of 40 min at a flow rate of 10 mL/min. Fractions containing the desired product were collected, frozen, and lyophilized to give compound **15** (5.9 mg, 34%) as a white solid.

¹H NMR (500 MHz, Deuterium Oxide) δ 5.14 (d, *J* = 3.7 Hz, 1H, H-1''), 4.53 (t, *J* = 7.4 Hz, 2H, H-1', H-1), 4.19 (d, *J* = 6.0 Hz, 2H, H-4', H-5''), 4.08 – 3.91 (m, 3H, H-6a, H-4'', H-3''), 3.88 – 3.51 (m, 16H), 3.40 – 3.30 (m, 1H, H-2). ¹³C NMR (500 MHz, Deuterium Oxide) δ 102.33, 101.66, 94.92, 78.05, 76.68, 74.54, 74.27, 73.89, 72.23, 70.32, 69.06, 68.77, 68.61, 68.03, 67.69, 64.29, 60.48, 60.41, 59.61, 50.02. MS (ESI), *m/z* 574.2090 (M + H)⁺ (C₂₀H₃₅N₃O₁₆ requires 574.2090). TLC; *R*_f 0.56 (2-propanol:AcOEt:H₂O=2:2:1).

2-(2-Azidoethoxy)ethyl α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-β-D-glucopyranoside (16)—Compound **13** (0.030 g, 0.0400 mmol) was allowed to react under the same condition as described for the preparation of deacetylated compound from compound **12** and the aliquot (0.0137 g, 0.03 mmol) of this compound was used for enzyme reaction to give compound **16** (6.7 mg, 36%) as a white solid.

^1H NMR (500 MHz, Deuterium Oxide) δ 5.16 (d, $J = 3.9$ Hz, 1H, H-1''), 4.54 (dd, $J = 7.9$, 5.1 Hz, 2H, H-1', H-1), 4.27 – 4.16 (m, 2H, H-4', H-5''), 4.15 – 3.92 (m, 4H), 3.92 – 3.57 (m, 17H), 3.57 – 3.48 (m, 2H, CH_2N_3), 3.41 – 3.31 (m, 1H, H-2). ^{13}C NMR (151 MHz, D_2O) δ 102.36, 101.61, 94.93, 78.10, 76.69, 74.55, 74.23, 73.88, 72.28, 70.33, 69.17, 69.08, 68.79, 68.66, 68.62, 68.23, 67.70, 64.30, 60.49, 60.42, 59.64, 49.67. MS (ESI), m/z 618.2350 ($\text{M} + \text{H}^+$) ($\text{C}_{22}\text{H}_{39}\text{N}_3\text{O}_{17}$ requires 618.2352). TLC; R_f 0.50 (2-propanol:AcOEt:H₂O=2:2:1).

2-[2-(2-azidoethoxy)ethoxy]ethyl α -D-galactopyranosyl-(1,3)- β -D-galactopyranosyl-(1,4)- β -D-glucopyranoside (17)—Compound **14** (0.059 g, 0.0743 mmol) was allowed to react under the same condition as described for the preparation of deacetylated compound from compound **12** and the aliquot (0.015 g, 0.03 mmol) of this compound was used for enzyme reaction to give compound **17** (14.3 mg, 68%) as a white solid.

^1H NMR (500 MHz, Deuterium Oxide) δ 5.17 (d, $J = 3.9$ Hz, 1H, H-1''), 4.55 (dd, $J = 7.9$, 2.7 Hz, 2H, H-1', H-1), 4.29 – 4.15 (m, 2H, H-4', H-5''), 4.12 – 3.93 (m, 4H), 3.93 – 3.58 (m, 21H), 3.56 – 3.49 (m, 2H, CH_2N_3), 3.37 (td, $J = 7.7$, 2.4 Hz, 1H, H-2). ^{13}C NMR (126 MHz, D_2O) δ 103.25, 102.49, 95.82, 79.01, 77.60, 75.44, 75.14, 74.77, 73.19, 71.23, 70.08, 69.98, 69.89, 69.68, 69.59, 69.52, 69.14, 68.60, 65.21, 61.37, 61.31, 60.55, 50.53. MS (ESI), m/z 662.2613 ($\text{M} + \text{H}^+$) ($\text{C}_{24}\text{H}_{43}\text{N}_3\text{O}_{18}$ requires 662.2614). TLC; R_f 0.47 (2-propanol:AcOEt:H₂O=2:2:1).

1-(2-aminoethyl) α -D-galactopyranosyl-(1,3)- β -D-galactopyranosyl-(1,4)- β -D-glucopyranoside)-2-ethoxycyclobutene-3,4-dione (1)—To a solution of **15** (0.0074 g, 0.0129 mmol) in MeOH (5 ml) was added 5% Pd-C (5.0 mg). The mixture was stirred under hydrogen atmosphere at room temperature for 24 h. The solution was filtered through a pad of celite, and then concentrated under reduced pressure to afford azide reduced crude compound, and this compound was used for next reaction for further purification. To a solution of amine compound in 50% aqueous EtOH (2ml) was added Diethyl squarate (0.0094 ml, 0.0636 mmol) and Et_3N (0.0072 ml, 0.0518 mmol), and stirred at room temperature for 24 hrs. The elute was concentrated and the residue was purified on a VYDAC C₁₈ reversed phase semipreparative (250 mm $\times$ 22 mm, 10–15 μm) HPLC column using water and CH_3CN mobile phases. A linear gradient was employed (95:5 H₂O/ CH_3CN $\rightarrow$ 5:95 H₂O/ CH_3CN) over a period of 40 min at a flow rate of 10 mL/min. Fractions containing the desired product were collected, frozen, and lyophilized to give compound **1** (0.0034 mg, 34% from compound **15**) as a colorless oil.

^1H NMR (600 MHz, Deuterium Oxide) δ 5.15 (t, $J = 3.0$ Hz, 1H, H-1''), 4.75 (ddd, 2H, OCH_2CH_3), 4.52 (ddt, $J = 6.6$, 4.9, 1.8 Hz, 2H, H-1', H-1), 4.20 (q, $J = 5.0$, 3.2 Hz, 2H, H-4', H-5''), 4.08 – 3.55 (m, 19H), 3.33 (s, 1H, H-2), 1.55 – 1.34 (m, 3H, CH_2CH_3). ^{13}C NMR (600 MHz, Deuterium Oxide) δ 191.76, 190.35, 188.52, 188.46, 183.00, 182.92, 176.96, 176.76, 173.28, 102.36, 101.70, 94.93, 78.11, 76.70, 74.87, 74.57, 74.30, 74.27, 73.96, 73.91, 72.31, 72.03, 70.46, 70.35, 70.15, 70.11, 69.24, 69.09, 68.90, 68.79, 68.63, 68.38, 67.71, 64.31, 60.50, 60.43, 59.65, 43.71, 43.64, 14.57, 14.53, 14.48. MS (ESI), m/z

672.2343 (M + H)⁺ (C₂₆H₄₁NO₁₉ requires 672.2345). TLC; R_f 0.13 (2-propanol:AcOEt:H₂O=2:2:1).

1-[2-(2-aminoethoxy)]ethyl α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-β-D-glucopyranoside-2-ethoxycyclobutene-3,4-dione (2)—Compound **16** (0.0067 g, 0.0108 mmol) was allowed to react under the same condition as described for the preparation of **1** to give **2** (0.0051 g, 66% from compound **16**) as a colorless oil.

¹H NMR (600 MHz, Deuterium Oxide) δ 5.16 (d, *J* = 3.7 Hz, 1H, H-1''), 4.77 – 4.70 (m, 2H, OCH₂CH₃), 4.52 (td, *J* = 9.1, 8.6, 4.1 Hz, 2H, H-1', H-1), 4.23 – 4.15 (m, 2H, H-4', H-5''), 4.11 – 3.52 (m, 23H), 3.34 (d, *J* = 8.3 Hz, 1H, H-2), 1.58 – 1.37 (m, 3H, OCH₂CH₃). ¹³C NMR (151 MHz, D₂O) δ 188.43, 182.94, 182.85, 176.91, 176.63, 173.27, 102.38, 101.65, 94.93, 78.16, 76.69, 74.87, 74.56, 74.29, 73.96, 72.29, 72.03, 70.46, 70.34, 70.17, 69.54, 69.24, 69.09, 68.96, 68.80, 68.63, 68.31, 68.24, 67.72, 64.31, 60.50, 60.42, 59.64, 43.47, 42.72, 14.51. MS (ESI), *m/z* 716.2609 (M + H)⁺ (C₂₈H₄₅NO₂₀ requires 716.2608). TLC; R_f 0.26 (2-propanol:AcOEt:H₂O=2:2:1).

1-[2-{2-(2-aminoethoxy)}ethoxy]ethyl α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-β-D-glucopyranoside-2-ethoxycyclobutene-3,4-dione (3)—Compound **17** (0.0089 g, 0.014 mmol) was allowed to react under the same condition as described for the preparation of **1** to give **3** (0.0058 g, 54% from compound **17**) as a colorless oil.

¹H NMR (600 MHz, Deuterium Oxide) δ 5.15 (dd, *J* = 3.8, 1.7 Hz, 1H, H-1''), 4.78 – 4.68 (m, 2H, OCH₂CH₃), 4.57 – 4.47 (m, 2H, H-1', H-1), 4.26 – 4.14 (m, 2H, H-4', H-5''), 4.10 – 3.53 (m, 27H), 3.42 – 3.28 (m, 1H, H-2), 1.54 – 1.36 (m, 3H, OCH₂CH₃). ¹³C NMR (151 MHz, D₂O) δ 191.76, 188.40, 182.90, 176.85, 176.61, 173.30, 102.36, 101.59, 94.92, 78.12, 76.70, 74.56, 74.26, 73.90, 72.29, 70.34, 70.16, 69.23, 69.18, 69.09, 68.97, 68.90, 68.79, 68.63, 68.27, 67.71, 64.31, 60.49, 60.42, 59.65, 43.47, 43.35, 14.52. MS (ESI), *m/z* 760.2867 (M + H)⁺ (C₃₀H₄₉NO₂₁ requires 760.2870). TLC; R_f 0.33 (2-propanol:AcOEt:H₂O=2:2:1).

Synthesis of 1-position modified α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy-β-D-glucopyranoside derivatives

2-Acetoamido-1,3,6-tri-O-acetyl-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-D-glucopyranose (19)—To a solution of *N*-acetyllactosamine **18** (0.5 g, 1.3 mmol) in pyridine (5 ml) was added acetic anhydride (2.84 ml, 30 mmol) and 4-dimethylaminopyridine (0.061 g, 1.3 mmol), and the mixture was stirred at room temperature for overnight. The mixture was concentrated in vacuo and the resulting residue purified by silica gel column chromatography (Toluene:AcOEt=1:9) to give compound **5** as yellow oil (0.73 g, 83%). The spectrum for compound **19** was the same as reported previously for the α isomer.³⁸

¹H NMR (600 MHz, Chloroform-*d*) δ 6.09 (d, *J* = 3.6 Hz, 1H, H-1), 5.74 (d, *J* = 9.2 Hz, 1H, NH), 5.36 (dd, *J* = 3.5, 1.2 Hz, 1H, H-4'), 5.23 (dd, *J* = 11.1, 8.4 Hz, 1H, H-3), 5.11 (dd, *J* = 10.5, 7.9 Hz, 1H, H-2'), 4.97 (dd, *J* = 10.4, 3.4 Hz, 1H, H-3'), 4.53 (d, *J* = 7.9 Hz, 1H,

H-1'), 4.44 – 4.32 (m, 2H, H-2, H-6a), 4.19 – 4.05 (m, 3H', H-6b, H-6a', H-6b'), 3.97 – 3.81 (m, 3H, H-5, H-4, H-5), 2.18, 2.15, 2.11, 2.09, 2.06, 1.96, 1.93 (7 x s, 21H, 7 x COCH₃). MS (ESI), m/z 678.2240 (M + H)⁺ (C₂₈H₃₉NO₁₈ requires 678.224). TLC; R_f 0.20 (AcOEt:Toluene=6:1).

2-Methyl-{3,6-di-O-acetyl-1,2-dideoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-D-glucopyrano}-[2,1-d]-oxazoline (20)—To a solution of peracetate **19** (0.49 g, 0.723 mmol) in 1,2-dichloroethane was added TMSOTf (0.161 ml, 0.889 mmol), and the resulting mixture was stirred at 50 °C for 5hrs. To the mixture was added Et₃N (0.145 ml, 1.04 mmol) and concentrated in vacuo. The residue was purified by silica gel column chromatography (Toluene:AcOEt:Et₃N=100:200:1) to afford **20** (0.304 g, 68%) as a yellow oil.

¹H NMR (600 MHz, Chloroform-*d*) δ 5.88 (d, *J* = 7.3 Hz, 1H, H-1), 5.61 (dd, *J* = 2.6, 1.1 Hz, 1H, H-3), 5.34 (dd, *J* = 3.6, 1.2 Hz, 1H, H-4'), 5.14 (dd, *J* = 10.4, 8.0 Hz, 1H, H-2'), 4.97 (dd, *J* = 10.4, 3.5 Hz, 1H, H-3'), 4.62 (d, *J* = 8.0 Hz, 1H, H-1'), 4.18 (dd, *J* = 12.0, 2.4 Hz, 1H, H-6a), 4.15 – 4.06 (m, 3H, H-2, H-6a', H-6b'), 4.04 (dd, *J* = 12.0, 5.9 Hz, 1H, H-6b), 3.92 (ddd, *J* = 7.6, 6.4, 1.2 Hz, 1H, H-5'), 3.63 (dt, *J* = 9.5, 1.4 Hz, 1H, H-5), 3.46 (ddd, *J* = 9.5, 5.7, 2.3 Hz, 1H, H-4), 2.13, 2.08, 2.07, 2.02, 2.01, 2.00, 1.94 (7 x s, 21H, 7 x COCH₃). MS (ESI), m/z 618.2031 (M + H)⁺ (C₂₆H₃₅NO₁₆ requires 618.2029). TLC; R_f 0.32 (CHCl₃:MeOH=20:1).

2-Azidoethyl (2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1,4)-O-2-acetamido-3,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (21)—To a solution of **20** (0.1 g, 0.162 mmol) and 2-azidoethanol (0.141 mg, 1.62 mmol) in 1,2-dichloroethane (10 ml) was added Pyridinium *p*-TsOH (0.005 g, 0.0199 mmol) and stirred at 70 °C for overnight. The mixture was cooled and neutralized with pyridine (0.25 ml, 3.1 mmol), and concentrated in vacuo. The residue was purified by silica gel column chromatography (n-hexanes:AcOEt=1:1) to afford **21** (0.067 g, 59%) as a colorless oil.

¹H NMR (600 MHz, Chloroform-*d*) δ 5.86 (d, *J* = 9.3 Hz, 1H, NH), 5.33 (dd, *J* = 3.5, 1.2 Hz, 1H, H-4'), 5.13 – 5.04 (m, 2H, H-2', H-3), 4.95 (dd, *J* = 10.5, 3.4 Hz, 1H, H-3'), 4.56 (d, *J* = 7.7 Hz, 1H, H-1'), 4.53 – 4.46 (m, 2H, H-1, H-6a), 4.13 – 3.93 (m, 5H, H-2, H-6b, H-6a', H-6b' OCHH), 3.86 (ddd, *J* = 7.5, 6.3, 1.3 Hz, 1H, H-5'), 3.77 (t, *J* = 8.6 Hz, 1H, H-4), 3.67 – 3.59 (m, 2H, OCHH, H-5), 3.45 (ddd, *J* = 13.4, 8.3, 3.3 Hz, 1H, CHHN₃), 3.24 (ddd, *J* = 13.4, 5.0, 3.2 Hz, 1H, CHHN₃), 2.12, 2.09, 2.05, 2.04 – 2.00, 1.94 (7 x s, 21H, 7 x COCH₃). ¹³C NMR (151 MHz, CDCl₃) δ 170.68, 170.48, 170.47, 170.44, 170.20, 170.12, 169.39, 101.11, 100.84, 75.88, 72.79, 72.44, 70.90, 70.78, 69.15, 68.26, 66.68, 62.17, 60.85, 53.32, 50.67, 23.34, 20.96, 20.94, 20.73, 20.71, 20.60. MS (ESI), m/z 705.2462 (M + H)⁺ (C₂₈H₄₀N₄O₁₇ requires 705.2461). TLC; R_f 0.35 (n-hexanes:acetone=1:1).

2-(2-Azidoethoxy)ethyl (2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1,4)-O-2-acetamido-3,6-di-O-acetyl-2-deoxy-β-D-glucopyranoside (22)—Oxazoline **20** (0.12 g, 0.194 mmol) and 2-(2-azidoethoxy)ethanol (0.254 ml, 1.94 mmol) were allowed to react under the same condition as described for the preparation of **21** to give **22** (0.108 g, 74%) as a white solid.

^1H NMR (600 MHz, Chloroform-*d*) δ 5.99 (d, J = 9.5 Hz, 1H, NH), 5.35 (dd, J = 3.4, 1.2 Hz, 1H, H-4'), 5.08 (ddd, J = 26.6, 10.1, 8.1 Hz, 2H, H-2', H-3), 4.96 (dd, J = 10.5, 3.4 Hz, 1H, H-3'), 4.58 (d, J = 7.9 Hz, 1H, H-1'), 4.52 – 4.40 (m, 2H, H-1, H-6a), 4.21 – 3.99 (m, 3H, H-6b, H-6a', H-6b'), 3.95 – 3.83 (m, 2H, H-2, OCHH), 3.83 – 3.63 (m, 8H, H-5', H-4, H-5, OCHH, 2 $\times$ OCH₂), 3.52 – 3.23 (m, 2H, CH₂N₃), 2.14, 2.11, 2.07, 2.05, 1.98 – 1.93 (7 $\times$ s, 21H, 7 $\times$ COCH₃). ^{13}C NMR (151 MHz, CDCl₃) δ 170.62, 170.50, 170.42, 170.27, 170.20, 170.11, 169.37, 101.38, 101.08, 75.95, 72.76, 72.75, 70.98, 70.76, 70.06, 69.17, 68.66, 66.70, 62.40, 60.87, 53.36, 51.02, 23.27, 20.96, 20.93, 20.72, 20.59. MS (ESI), m/z 749.2726 ($M + H$)⁺ (C₃₀H₄N₄O₁₈ requires 749.2723). TLC; R_f 0.40 (n-hexanes:acetone=1:1).

2-[2-(2-Azidoethoxy)ethoxy]ethyl (2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-(1,4)-O-2-acetamido-3,6-di-O-acetyl-2-deoxy- β -D-glucopyranoside (23)—

Oxazoline **20** (0.079 g, 0.128 mmol) and 2-[2-(2-azidoethoxy)ethoxy]ethanol (0.224 mg, 1.28 mmol) were allowed to react under the same condition as described for the preparation of **21** to give **23** (0.040 g, 40%) as a colorless oil.

^1H NMR (600 MHz, Chloroform-*d*) δ 6.28 (d, J = 9.6 Hz, 1H, NH), 5.33 (dd, J = 3.5, 1.2 Hz, 1H, H-4'), 5.09 (dd, J = 10.5, 7.9 Hz, 1H, H-2'), 5.01 (dd, J = 10.2, 8.7 Hz, 1H, H-3), 4.94 (dd, J = 10.4, 3.4 Hz, 1H, H-3'), 4.64 (d, J = 8.3 Hz, 1H, H-1), 4.52 – 4.41 (m, 2H, H-1', H-6a), 4.14 – 4.04 (m, 4H, H-2, H-6b, H-6a', H-6b'), 3.89 – 3.54 (m, 15H, H-5, H-4, H-5', OCH₂ $\times$ 3, CH₂O $\times$ 2), 3.50 (ddd, J = 5.3, 4.4, 0.9 Hz, 2H, CH₂N₃), 2.12, 2.10, 2.06 – 2.01, 1.95 (7 $\times$ s, 21H, 7 $\times$ COCH₃). ^{13}C NMR (151 MHz, CDCl₃) δ 170.60, 170.57, 170.52, 170.44, 170.23, 170.14, 169.35, 102.04, 101.23, 76.33, 73.51, 72.68, 71.79, 71.08, 70.75, 70.60, 69.95, 69.23, 68.78, 66.72, 62.51, 60.87, 53.58, 50.60, 23.11, 21.01, 21.00, 20.76, 20.74, 20.63. MS (ESI), m/z 793.2985 ($M + H$)⁺ (C₃₂H₄₈N₄O₁₉ requires 793.2974). TLC; R_f 0.50 (n-hexane:acetone=1:1).

2-Azidoethyl α -D-galactopyranosyl-(1,3)- β -D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy- β -D-glucopyranoside (24)—

To a solution of **21** (0.0187 g, 0.0265 mmol) in dry MeOH (10 ml) was added 0.5 M NaOMe (0.5 ml, 0.25 mmol). The mixture was stirred at room temperature for 5 h, and then neutralized with CH₃COOH (0.017 ml, 0.3 mmol). The mixture was concentrated in vacuo, and the residue was purified on a VYDAC C₁₈ reversed phase semi preparative (250 mm $\times$ 22 mm, 10–15 μ m) HPLC column using H₂O and 0.1% TFA in CH₃CN mobile phases. A linear gradient was employed (95:5 H₂O/0.1% TFA in CH₃CN $\rightarrow$ 5:95 H₂O/0.1% TFA in CH₃CN) over a period of 40 min at a flow rate of 10 mL/min. Fractions containing the desired product were collected, frozen, and lyophilized to give deacetylated compound quantitatively. To a solution of 5 mM UDP-Galactose and 4 mM deacetylated compound (0.0118 g, 0.0192 mmol) in 50 mM Tris-HCl (pH 7.0) supplemented with 10 mM MnCl₂ was added 1,3 α GalT (20 μ g/mL) to a final volume of 7.5 ml. The solution was incubated at 37°C with agitation and reaction progress was monitored by TLC. When the deacetylated compound was consumed, 1,3 α GalT was removed using an Amicon 4 filter (MWCO 10-kDa) by centrifugation at 7,830 rpm and room temperature for 15 min. Filtrates were then concentrated in vacuo and the residue was dissolved in H₂O and passed through a chloride

anion-exchange column [Dowex 1 (Cl^-)]. The eluate was concentrated and the residue was also purified on a VYDAC C_{18} reversed phase semi preparative (250 mm $\times$ 22 mm, 10–15 μm) HPLC column using H_2O and 0.1% TFA in CH_3CN mobile phases. A linear gradient was employed (95:5 H_2O /0.1% TFA in CH_3CN $\rightarrow$ 5:95 H_2O /0.1% TFA in CH_3CN) over a period of 40 min at a flow rate of 10 mL/min. Fractions containing the desired product were pooled, frozen, and lyophilized to afford compound **24** (5.1 mg, 32%) as a white solid.

^1H NMR (600 MHz, Deuterium Oxide) δ 5.07 (d, J = 3.9 Hz, 1H, H-1''), 4.53 (d, J = 8.3 Hz, 1H, H-1'), 4.47 (d, J = 7.8 Hz, 1H, H-1), 4.16 – 4.06 (m, 2H, H-4', H-5''), 3.98 (ddd, J = 11.5, 5.6, 3.0 Hz, 1H), 3.94 (d, J = 3.6 Hz, 1H), 3.92 (d, J = 2.1 Hz, 1H), 3.87 (dd, J = 10.4, 3.3 Hz, 1H), 3.81 – 3.50 (m, 14H), 3.41 (ddd, J = 13.9, 7.7, 3.0 Hz, 1H, CHHN_3), 3.34 (ddd, J = 13.8, 5.8, 3.0 Hz, 1H, CHHN_3), 1.97 (s, 3H, COCH_3). ^{13}C NMR (151 MHz, D_2O) δ 174.19, 102.32, 100.50, 94.94, 78.19, 76.70, 74.57, 74.30, 2.06, 71.56, 70.35, 69.11, 68.63, 68.27, 67.70, 64.32, 61.99, 60.50, 60.43, 59.62, 54.50, 49.87, 21.76. MS (ESI), m/z 615.2353 ($\text{M} + \text{H}^+$) ($\text{C}_{22}\text{H}_{38}\text{N}_4\text{O}_{16}$ requires 615.2355). TLC; R_f 0.22 (2-propanol:AcOEt: H_2O =2:2:1).

2-(2-Azidoethoxy)ethyl α -D-galactopyranosyl-(1,3)- β -D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy- β -D-glucopyranoside (25)—Compound **22** (0.079 g, 0.105 mmol) was allowed to react under the same condition as described for the preparation of compound **24**. The aliquot (0.015 g, 0.03 mmol) of deacetylated compound from **22** gave compound **25** (12.2 mg, 62% from compound **22**) as a white solid.

^1H NMR (600 MHz, Deuterium Oxide) δ 5.11 (d, J = 3.9 Hz, 1H, H-1''), 4.55 (dd, J = 8.3, 1.6 Hz, 1H, H-1'), 4.51 (d, J = 7.9 Hz, 1H, H-1), 4.19 – 4.11 (m, 2H, H-4', H-5''), 4.01 – 3.87 (m, 4H), 3.85 – 3.59 (m, 17H), 3.55 (d, J = 7.0 Hz, 1H), 3.49 – 3.43 (m, 2H, CH_2N_3), 2.01 (s, 3H, COCH_3). ^{13}C NMR (151 MHz, D_2O) δ 174.04, 102.30, 100.44, 94.93, 78.18, 76.69, 74.53, 74.21, 72.04, 70.32, 69.08, 68.80, 68.62, 67.69, 64.31, 60.48, 60.42, 59.62, 54.53, 49.71, 21.66. MS (ESI), m/z 659.2617 ($\text{M} + \text{H}^+$) ($\text{C}_{24}\text{H}_{42}\text{N}_4\text{O}_{17}$ requires 659.2618). TLC; R_f 0.31 (2-propanol:AcOEt: H_2O =2:2:1).

2-(2-Azidoethoxy)ethyl α -D-galactopyranosyl-(1,3)- β -D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy- β -D-glucopyranoside (25)—In an alternative method for the generation of compound **25**, the deacetylated compound from **22** was allowed to react in a coupled enzyme system containing both 1,3 α GalT and GalE. To a solution of 5 mM UDP-Glucose, 4 mM deacetylated compound (0.015 g, 0.03 mmol) in 50 mM Tris-HCl (pH 7.0) supplemented with 10 mM MnCl_2 was added 1,3 α GalT (20 $\mu\text{g/mL}$) and GalE (20 $\mu\text{g/mL}$)²² to a final volume of 7.5 ml. The same work-up procedure as described for compound **24** afforded compound **25** (11.2 mg, 57%) as a white solid.

2-[2-(2-azidoethoxy)ethoxy]ethyl α -D-galactopyranosyl-(1,3)- β -D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy- β -D-glucopyranoside (26)—The deacetylated compound from **23** was allowed to react under the same conditions as described for the preparation of compound **25** to give compound **26** (11 mg, 54% from compound **23**) as a white solid.

¹H NMR (600 MHz, Deuterium Oxide) δ 5.15 (d, *J* = 3.9 Hz, 1H, H-1''), 4.63 – 4.51 (m, 1H, H-1'), 4.48 (d, *J* = 7.9 Hz, 1H, H-1), 4.25 – 4.16 (m, 1H, H-4'), 4.08 – 3.89 (m, 4H), 3.90 – 3.48 (m, 25H, CH₂N₃), 2.05 (s, 3H, COCH₃). ¹³C NMR (151 MHz, D₂O) δ 174.03, 102.32, 100.47, 94.94, 78.21, 76.70, 74.57, 74.24, 72.07, 70.48, 70.35, 69.15, 68.84, 68.64, 68.50, 67.71, 64.32, 60.50, 59.65, 54.55, 49.74, 21.69. MS (ESI), *m/z* 703.2879 (M + H)⁺ (C₂₆H₄₆N₄O₁₈ requires 703.288).

1-(2-aminoethyl) α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy-β-D-glucopyranoside-2-ethoxycyclobutene-3,4-dione (4)—

To a solution of **24** (0.0038 g, 0.00647 mmol) in MeOH (5 ml) was added 5% Pd-C (5.0 mg). The mixture was stirred under hydrogen atmosphere at room temperature for 24 h. The solution was filtered through a pad of celite, and then concentrated under reduced pressure to afford azide reduced crude compound, and this compound was used for next reaction for further purification. To a solution of amine compound in 50% aqueous EtOH (2ml) was added Diethyl squarate (0.0047 ml, 0.032 mmol) and Et₃N (0.0035 ml, 0.023 mmol), and stirred at room temperature for 24 hrs. The elute was concentrated and the residue was purified on a VYDAC C₁₈ reversed phase semi preparative (250 mm × 22 mm, 10–15 μm) HPLC column using water in CH₃CN mobile phases. A linear gradient was employed (95:5 H₂O/CH₃CN → 5:95 H₂O/CH₃CN) over a period of 40 min at a flow rate of 10 mL/min. Fractions containing the desired product were collected, frozen, and lyophilized to give compound **4** (2.5 mg, 54% from compound **24**) as a colorless oil.

¹H NMR (600 MHz, Deuterium Oxide) δ 5.16 (d, *J* = 3.9 Hz, 1H, H-1''), 4.75 (ddd, 2H, OCH₂CH₃), 4.61 – 4.48 (m, 2H, H-1', H-1), 4.26 – 4.16 (m, 2H, H-4', H-5''), 4.10 – 3.92 (m, 4H), 3.91 – 3.53 (m, 16H), 2.00 (s, 3H, COCH₃), 1.46 (q, *J* = 7.5 Hz, 3H, CH₂CH₃). MS (ESI), *m/z* 713.2607 (M + H)⁺ (C₂₈H₄₄N₂O₁₉ requires 713.2611). TLC; R_f 0.32 (2-propanol:AcOEt:H₂O=1:1:1).

1-[2-(2-aminoethoxy)]ethyl α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy-β-D-glucopyranoside-2-ethoxycyclobutene-3,4-dione (5)—

Compound **25** (0.0112 g, 0.0177 mmol) was allowed to react under the same condition as described for the preparation of **4** to give **5** (0.0063 g, 47%) as a colorless oil.

¹H NMR (600 MHz, Deuterium Oxide) δ 5.16 (d, *J* = 3.9 Hz, 1H, H-1''), 4.77 – 4.67 (m, 2H, OCH₂CH₃), 4.57 (dd, *J* = 13.2, 8.1 Hz, 2H, H-1', H-1), 4.27 – 4.15 (m, 2H, H-4', H-5''), 4.08 – 3.90 (m, 4H), 3.91 – 3.47 (m, 20H), 2.04 (s, 3H, COCH₃), 1.46 (q, *J* = 7.4 Hz, 3H, CH₂CH₃). ¹³C NMR (151 MHz, D₂O) δ 188.46, 173.92, 173.17, 102.33, 100.53, 94.94, 78.23, 77.99, 76.69, 74.87, 74.56, 74.29, 72.04, 71.98, 70.35, 70.17, 69.23, 69.10, 68.79, 68.63, 68.53, 68.47, 68.06, 67.71, 64.31, 60.49, 60.42, 59.67, 54.51, 43.50, 21.67, 14.51. MS (ESI), *m/z* 757.2873 (M + H)⁺ (C₃₀H₄₈N₂O₂₀ requires 757.2875). TLC; R_f 0.41 (2-propanol:AcOEt:H₂O=1:1:1).

1-[2-{2-(2-aminoethoxy)}ethoxy]ethyl α-D-galactopyranosyl-(1,3)-β-D-galactopyranosyl-(1,4)-O-2-acetamido-2-deoxy-β-D-glucopyranoside-2-ethoxycyclobutene-3,4-dione (6)—

Compound **26** (0.0114 g, 0.0168 mmol) was

allowed to react under the same condition as described for the preparation of **4** to give **6** (0.01 g, 74%) as a colorless oil.

^1H NMR (600 MHz, Deuterium Oxide) δ 5.16 (d, J = 3.9 Hz, 1H, H-1''), 4.77 – 4.67 (m, 2H, OCH_2CH_3), 4.57 (dd, J = 13.2, 8.1 Hz, 2H, H-1', H-1), 4.27 – 4.15 (m, 2H, H-4', H-5''), 4.08 – 3.90 (m, 4H), 3.91 – 3.47 (m, 24H), 2.04 (s, 3H, COCH_3), 1.46 (q, J = 7.4 Hz, 3H, CH_2CH_3). ^{13}C NMR (151 MHz, D_2O) δ 188.38, 173.95, 102.41, 100.53, 94.94, 74.87, 74.57, 74.29, 72.07, 72.02, 70.48, 70.35, 70.16, 69.30, 69.21, 69.16, 68.98, 68.80, 68.64, 68.56, 68.07, 67.71, 64.32, 60.50, 60.43, 59.58, 54.53, 43.48, 21.69, 14.53. MS (ESI), m/z 801.3131 ($\text{M} + \text{H}$) $^+$ ($\text{C}_{32}\text{H}_{52}\text{N}_2\text{O}_{21}$ requires 801.3135). TLC; R_f 0.13 (2-propanol:AcOEt:H $_2$ O=1:1:1).

Animals

Mice used have disrupted (knockout) α 1,3galactosyltransferase genes¹⁶ and are referred to as knockout (KO) mice (6–10 week old). Mice were group-housed in an AAALAC-accredited vivarium containing temperature- and humidity-controlled rooms, with mice kept on a reverse light cycle (lights on: 9PM-9AM). All experiments were performed during the dark phase, generally between 1PM-4PM. General health was monitored by both the scientists and veterinary staff at The Scripps Research Institute. All studies were performed in compliance with the Scripps Institutional Animal Care and Use Committee, and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Conjugation of Haptens

Dialyzed KLH, TT or BSA in 0.5M Borate buffer (pH 9.0) was added to the hapten [ca. 447 (compound **1**), 420 (compound **2**), 393 (compound **3**) equiv. for KLH, 205 (compound **4**), 193 (compound **5**), 180 (compound **6**) equiv. for TT, and 92 (compound **3**), 87 (compound **6**) equiv. for BSA] to give a final concentration of 1.25 mg/mL in 0.5M Borate buffer (pH 9.0) and the solutions mixed (rt, 24 h). In order to quantify copy number (hapten density) for each **3**-BSA and **6**-BSA conjugates, samples were submitted for MALDI-TOF analysis and compared MW of **3**-BSA or **6**-BSA and unmodified BSA, respectively, as per the formula: copy number = (MW α Gal BSA – MW BSA) / (MW α Gal – MW EtOH); MW α Gal = 759 (compound **3**), 800 (compound **6**) Da, MW EtOH = 46 Da; MW **3**-BSA = 76,514 Da, MW **6**-BSA = 78,102, MW BSA = 66,432 Da (see supplementary information 2). The resulting protein conjugates were dialyzed into PBS (pH 7.4) at 4 °C. KLH and TT conjugates were used for immunization; BSA conjugates were used for ELISA plate coating.

Vaccine formulation/administration and blood collection

On a per mouse basis, 50 μg of KLH-conjugate (or 50 μg of TT-conjugate) in ~50 μL PBS pH 7.4 was combined with 50 μL of Alhydrogel® (10 mg/mL, Invivogen). The resulting suspension was mixed and subsequently administered to mice intraperitoneally on days 0, 14, and 28 for KLH-conjugates (or 0, 28, 42 for TT-conjugate). Each mouse was bled (via retro-orbital sinus) on days 28 and 42 for KLH-conjugates (or 37 and 51 for TT-conjugates). Blood samples were then centrifuged at 10,000 rpm for 10 min to collect sera.

ELISA

Production of anti- α Gal IgG antibody was evaluated by ELISA. Microtiter plates (Costar 3690) were incubated with coating antigen-BSA in PBS (4 μ g/mL, 25 μ L) (18 h, 37 °C). Then, 5% nonfat milk in PBS (30 min, 37 °C) was added to block nonspecific binding. Mouse sera in 2% BSA were serially diluted across the plate before incubation in a moist chamber (24 h, 4 °C). The plate was washed with dH₂O before incubation with peroxidase-conjugated donkey anti-mouse IgG (SouthernBiotech) in a moist chamber (2 h, 25 °C). The plates were further washed with dH₂O before being developed with using TMB (Thermo Pierce) and the absorbance at 450 nm measured on a microplate reader (SpectraMax M2e Molecular Devices). Titers were calculated as the dilution corresponding to 50% of the maximum absorbance from a plot of the absorbance versus log(dilution) using GraphPad Prism 6. Competitive ELISA was also performed in a similar manner but with an added step: serum was incubated with dilution of compounds 2 and 5 (0, 0.6, 6.0, 60 μ M) in hapten-BSA coated plates for 24 h (4°C).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Prof. George Peng Wang for his generous gift of enzyme plasmids. Funding for this work was provided by the NIH, NIDA R01DA008590 (to K.D.J) and NCATS CTSA Award UL1 TR001114 (to N.T.J). The authors acknowledge Dr. Major Gooyit for helpful discussions.

Notes and References

1. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Proc Natl Acad Sci USA. 1987; 84:1369. [PubMed: 2434954]
2. Galili U, Shohet USB, Kobrin E, Stults CLM, Macher BA. J Biol Chem. 1988; 263:17755. [PubMed: 2460463]
3. Galili U, Macher BA, Buehler J, Shohet SB. J Exp Med. 1985; 162:573. [PubMed: 2410529]
4. Galili U, Rachmilewitz EA, Peleg A, Flechner I. J Exp Med. 1984; 160:1519. [PubMed: 6491603]
5. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. Blood. 1993; 82:2485. [PubMed: 7691263]
6. Good H, Cooper DKC, Malcolm AJK, Ippolito RM, Koren E, Neethling FA. Transplant Proc. 1992; 24:559. [PubMed: 1566430]
7. Sandrin M, Vaughan HA, Dabkowski PL, McKenzie IFC. Proc Natl Acad Sci USA. 1993; 90:11391. [PubMed: 7504304]
8. Collins BH, Cotterell AH, McCurry KR, Alvarado CG, Magee JC, Parker W, Platt JL. J Immunol. 1995; 154:5500. [PubMed: 7537308]
9. Sachs DH, Sykes M, Robson SC, Cooper DK. Adv Immunol. 2001; 79:129. [PubMed: 11680007]
10. Thall AD, Maly P, Lowe JB. J Biol Chem. 1995; 270:21437. [PubMed: 7545161]
11. Abdel-Motal UM, Wigglesworth K, Galili U. Vaccine. 2009; 27:3072. [PubMed: 19428921]
12. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. Blood. 1993; 82:2485. [PubMed: 7691263]
13. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA. Mol Immunol. 2009; 47:233. [PubMed: 19828202]
14. Agostino M, Sandrin MS, Thompson PE, Yuriev E, Ramsland PA. Glycobiology. 2010; 20:724. [PubMed: 20176856]
15. Cooper DKC, Good H, Koren E, Oriol R, Malcolm AJ, Ippolito RM, Neethling FA, Ye Y, Romano E, Zuhdi N. Transpl Immunol. 1993; 1:198. [PubMed: 7521740]

16. Cooper DKC. *Glycobiology*. 2016; 26:571. [PubMed: 26935763]
17. Vic G, Tran CH, Scigelova M, Crout DHG. *Chem Commun*. 1997; 2:169.
18. Wang JQ, Chen X, Zhang W, Zacharek S, Chen Y, Wang PG. *J Am Chem Soc*. 1999; 121:8174.
19. Ramsland PA, Farrugia W, Yuriev E, Edmundson AB, Sandrin MS. *Cell Mol Biol*. 2003; 49:307. [PubMed: 12887109]
20. Wurm FR, Klok HA. *Chem Soc Rev*. 2013; 42:8220. [PubMed: 23873344]
21. Hou S, Saksena R, Kovac P. *Carbohydr Res*. 2008; 343:196. [PubMed: 18048016]
22. Owen RM, Carlson CB, Xu J, Mowery P, Fasella E, Kiessling LL. *ChemBioChem*. 2007; 8:68. [PubMed: 17154219]
23. Schocker NS, Portillo S, Brito CRN, Marques AF, Almeida IC, Michael K. *Glycobiology*. 2016; 26:39. [PubMed: 26384953]
24. Wang JQ, Chen X, Zhang W, Zacharek S, Chen Y, Wang PG. *J Am Chem Soc*. 1999; 121:8174.
25. Kato H, Uzawa H, Nagatsuka T, Kondo S, Sato K, Ohsawa I, Kanamori-kataoka M, Takei Y, Ota S, Furuno M, Dohi H, Nishida Y, Seto Y. *Carbohydr Res*. 2011; 346:1820. [PubMed: 21784417]
26. Chang CWT, Hui YH, Elchert B, Wang J, Li J, Rai R. *Organic Lett*. 2002; 4:4603.
27. Yudina ON, Sherman AA, Nifantiev NE. *Carbohydr Res*. 2001; 332:363. [PubMed: 11438093]
28. Wrodnigg TM, Stutz AE. *Angew Chem Int Ed*. 1999; 38:827.
29. Stutz AE, Dekany G, Eder B, Illaszewicz C, Wrodnigg TM. *J Carbohydr Chem*. 2003; 22:253.
30. Gao Y, Eguchi A, Kakehi K, Lee YC. *Bioorg Med Chem*. 2005; 13:6151–6157. [PubMed: 16054373]
31. Kool M, Soullie T, Nimwegen M, Willart MAM, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. *J Exp Med*. 2008; 205:869. [PubMed: 18362170]
32. Huang YL, Hung JT, Cheung SKC, Lee HY, Chu KC, Li ST, Lin YC, Ren CT, Cheng TJR, Hsu TL, Yu AL, Wu CY, Wong CH. *Proc Natl Acad Sci USA*. 2013; 110:2517. [PubMed: 23355685]
33. Nozawa S, Xing PX, Wu GD, Gochi E, Jonker MK, Swensson J, Starnes VA, Sandrin M, McKenzie IFC, Cramer DV. *Transplantation*. 2001; 72:147. [PubMed: 11468550]
34. Astronomo RD, Burton DR. *Nat Rev Drug Discov*. 2010; 9:308. [PubMed: 20357803]
35. Milland J, Yuriev E, Xing PX, McKenzie IFC, Ramsland PA, Sandrin MS. *Immunol Cell Biol*. 2007; 85:623. [PubMed: 17724458]
36. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. *Anal Biochem*. 1985; 150:76. [PubMed: 3843705]
37. Wengatz I, Schmid RD, Kreißig S, Wittmann C, Hock B, Ingendoh A, Hillenkamp F. *Anal Lett*. 1992; 25:1983.
38. Range G, Krahmer R, Welzel P, Muller D, Herrmann GF, Kragl U, Wandrey C, Makus A, Heijenoort YV, Heijenoort JV. *Tetrahedron*. 1997; 53:1695.

Figure 1.
Structures of α Gal trisaccharide epitope

Figure 2.
 Synthetic strategy of the Gal α (1,3)Gal β (1,4)Glc and Gal α (1,3)Gal β (1,4)GlcNAc epitope.

Figure 3.
Two enzymatic system of synthesis for Gal α (1,3)Gal β (1,4)GlcNAc type epitope

Figure 4. Midpoint anti-Gal antibody titers from compound **1**- (n=2), **2**- (n=4), and **3**-KLH (n=4) vaccinated mice, and compound **4**- (n=7), **5**- (n=7), and **6**-TT (n=7) vaccinated mice. (a) Anti-**3** IgG titers and (b) anti-**3** IgM (37 days) by ELISA using **3**-BSA as a coating antigen. (c) Anti-**6** IgG titers and (d) anti-**6** IgM (51 days) by ELISA using **6**-BSA as a coating antigen.

Figure 5.

The bar graph for the competitive interaction between anti-5 antibody sera and compound 6-BSA conjugate with compound 2 (a) and compound 5 (b) as competitors, which are presented at concentrations of 0, 0.6, 6.0, and 60 μM .

Scheme 1.

Reagents and conditions: (i) 2-chloroethanol, $\text{BF}_3\text{-Et}_2\text{O}$, CH_2Cl_2 , 0°C then rt, overnight, 52%; (ii) (a) $\text{N}_2\text{H}_4\text{-OAc}$, DMF, rt, 4 h; (b) DBU, Cl_3CCN , CH_2Cl_2 , 0°C then rt, 2 h, 58% for 2 steps; (iii) 2-(2-chloroethoxy)ethanol or 2-[2-(2-chloroethoxy)ethoxy]ethanol, $\text{BF}_3\text{-Et}_2\text{O}$, CH_2Cl_2 , 0°C then rt, overnight, 58% (n=2), 44% (n=3); (iv) NaN_3 , DMF, 80°C , 48 h, 52–84%. (v) (a) MeONa, MeOH, rt, 5 h; (b) 4mM substrates, 20 $\mu\text{g/mL}$ $\alpha 1,3\text{GalT}$, 5 mM UDP-galactose, 10 mM MnCl_2 , 10 mM Tris-HCl (pH 7.0), 37°C for 72–168 h, 34–54%; (vi) (a) $\text{H}_2/\text{Pd-C}$, MeOH, rt, 24 h; (b) Squaric acid ethylester, Et_3N , 50% aq. EtOH, rt, 24h, 39–54%.

Scheme 2.

Reagents and conditions: (i) Ac_2O , DMAP, pyridine, rt, overnight, 83%; (ii) TMSOTf, $\text{ClCH}_2\text{CH}_2\text{Cl}$, 50°C , 24h, 68%; (iii) 2-azidoethanol, 2-(2-azidoethoxy)ethanol or 2-[2-(2-azidoethoxy)ethoxy]ethanol, PPTS, $\text{ClCH}_2\text{CH}_2\text{Cl}$, 70°C , 24h, 40–74%; (iv) (a) MeONa, MeOH, rt, 5 h; (b) 4 mM substrates, $20\text{ }\mu\text{g/mL}$ $\alpha 1,3\text{GalT}$, 5 mM UDP-galactose, MnCl_2 , 10 mM Tris-HCl (pH 7.0), 37°C for 72–168 h, 32–62%; (v) (a) MeONa, MeOH, rt, 5 h; (b) 4 mM substrates, $20\text{ }\mu\text{g/mL}$ $\alpha 1,3\text{GalT}$, $20\text{ }\mu\text{g/mL}$ GalE, 5 mM UDP-glucose, MnCl_2 , 10 mM Tris-HCl (pH 7.0), 37°C for 72–168 h, 52–57% (vi) (a) $\text{H}_2/\text{Pd-C}$, MeOH, rt, 24 h; (b) Squaric acid ethylester, Et_3N , 50% aq. EtOH, rt, 24h, 47–74%.